Literature DB >> 33681468

The ambiguous role of mannose-binding lectin (MBL) in human immunity.

Namarta Kalia1,2, Jatinder Singh1, Manpreet Kaur3.   

Abstract

Mannose-binding lectin (MBL) and lectin complement pathway have become targets of increasing clinical interest. Many aspects of MBL have been recently explored, including the structural properties that allow it to distinguish self from non-self/altered-self structures. Experimental evidences have declared the additional 5'- and 3'-variants that in amalgamation with well-known secretor polymorphisms change MBL function and concentration. Moreover, the current review highlights the differential behavior of MBL on exposure with extra/intracellular pathogens and in autoimmune diseases, stressing the fact that "high MBL levels can increase diseases susceptibility," a paradox that needs justification. Attributable to these discrepancies, no absolute level of MBL deficiency could be defined so far and thus must be interpreted for specific diseases through case-control population-specific designs. Overall, it is evident that further research is needed about MBL and the lectin pathway of complement. Particularly, the transformative role of MBL over evolution is of interest and its role with regard to pathogenesis of different diseases and potential therapeutic targets within the respective pathways should be further explored. Apart from this, it is necessary to adopt an extensive locus-wide methodology to apprehend the clinical significance of MBL2 polymorphisms in a variety of infectious diseases by the future studies.
© 2021 Namarta Kalia et al., published by De Gruyter.

Entities:  

Keywords:  3′UTR; 5′ near gene; autoimmune diseases; functional SNPs; infectious diseases; phagocytosis and MBL patents; single nucleotide polymorphisms; variants

Year:  2021        PMID: 33681468      PMCID: PMC7917369          DOI: 10.1515/med-2021-0239

Source DB:  PubMed          Journal:  Open Med (Wars)


  109 in total

1.  Complement receptor type 1 (CR1, CD35) is a receptor for C1q.

Authors:  L B Klickstein; S F Barbashov; T Liu; R M Jack; A Nicholson-Weller
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

2.  Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes.

Authors:  Jeanette Seyfarth; Peter Garred; Hans O Madsen
Journal:  Mol Immunol       Date:  2005-08-19       Impact factor: 4.407

3.  Mannose-binding lectin serum levels in patients with systemic lupus erythematosus: association with thrombocytopaenia and seizure.

Authors:  J Z Cieslinski; T L Skare; R Nisihara; I J De Messias-Reason; S R R Utiyama
Journal:  Lupus       Date:  2017-08-08       Impact factor: 2.911

4.  Novel collectin/C1q receptor mediates mast cell activation and innate immunity.

Authors:  Brian T Edelson; Thomas P Stricker; Zhengzhi Li; S Kent Dickeson; Virginia L Shepherd; Samuel A Santoro; Mary M Zutter
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

5.  Interaction of human mannose-binding lectin (MBL) with Yersinia enterocolitica lipopolysaccharide.

Authors:  Katarzyna Kasperkiewicz; Anna S Swierzko; Marcin A Bartlomiejczyk; Maciej Cedzynski; Magdalena Noszczynska; Katarzyna A Duda; Mateusz Michalski; Mikael Skurnik
Journal:  Int J Med Microbiol       Date:  2015-07-08       Impact factor: 3.473

6.  Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease.

Authors:  Peter Garred; Tacjana Pressler; Susanne Lanng; Hans O Madsen; Claus Moser; Inga Laursen; Flemming Balstrup; Claus Koch; Christian Koch
Journal:  Pediatr Pulmonol       Date:  2002-03

7.  Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study.

Authors:  H Valdimarsson; T Vikingsdottir; P Bang; S Saevarsdottir; J E Gudjonsson; O Oskarsson; M Christiansen; L Blou; I Laursen; C Koch
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

8.  Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL.

Authors:  M Matsushita; M Hijikata; Y Ohta; K Iwata; M Matsumoto; K Nakao; K Kanai; N Yoshida; K Baba; S Mishiro
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

Review 9.  Signaling by myeloid C-type lectin receptors in immunity and homeostasis.

Authors:  David Sancho; Caetano Reis e Sousa
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

10.  Broad-spectrum capture of clinical pathogens using engineered Fc-mannose-binding lectin enhanced by antibiotic treatment.

Authors:  Benjamin T Seiler; Mark Cartwright; Alexandre L M Dinis; Shannon Duffy; Patrick Lombardo; David Cartwright; Elana H Super; Jacqueline Lanzaro; Kristen Dugas; Michael Super; Donald E Ingber
Journal:  F1000Res       Date:  2019-01-25
View more
  3 in total

1.  Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy.

Authors:  Nicola Iacomino; Fiammetta Vanoli; Rita Frangiamore; Marta Ballardini; Letizia Scandiffio; Federica Bortone; Francesca Andreetta; Fulvio Baggi; Pia Bernasconi; Carlo Antozzi; Paola Cavalcante; Renato Mantegazza
Journal:  Biomedicines       Date:  2022-06-09

Review 2.  Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.

Authors:  Md Nasir Ahmed; Rownak Jahan; Veeranoot Nissapatorn; Polrat Wilairatana; Mohammed Rahmatullah
Journal:  Biomed Pharmacother       Date:  2021-12-07       Impact factor: 7.419

3.  Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis.

Authors:  Mariangela Pampalone; Giampiero Vitale; Salvatore Gruttadauria; Giandomenico Amico; Gioacchin Iannolo; Bruno Douradinha; Alessandra Mularoni; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.